Systemic therapy for patients at high risk for recurrent melanoma
2006
Concerns About High-Dose Interferon for Melanoma
Commentary
Evidence: low
Author Information
Author(s): Kenneth S. Wilson
Primary Institution: BCCA Vancouver Island Centre
Hypothesis
Is high-dose interferon superior to GM2 vaccine as adjuvant therapy for high-risk melanoma?
Conclusion
The review suggests that high-dose interferon does not show a significant overall survival benefit based on the E1684 trial data.
Supporting Evidence
- The E1684 trial is negative for overall survival benefit at a median follow-up of 12.6 years.
- High-dose interferon has not shown a significant improvement in overall survival according to the data.
- The E1694 trial results are considered too preliminary to draw firm conclusions.
Takeaway
The study questions whether a treatment called high-dose interferon really helps people with melanoma, based on some old data that says it might not.
Potential Biases
The interpretation of the E1684 trial results may be biased as it is viewed positively despite the insignificant p-value.
Limitations
The conclusions are based on incomplete data and lack of published follow-up data on the E1694 trial.
Statistical Information
P-Value
0.09
Statistical Significance
p = 0.09
Want to read the original?
Access the complete publication on the publisher's website